YES — Medicare covers prostate cancer screening with an annual PSA blood test at no cost for men 50 and older. But whether you should be screened is one of the most genuinely individualized decisions in senior men’s health. Prostate cancer screening in 2026 looks very different from a decade ago: we now have MRI before biopsy, blood tests that reduce false alarms, and 15-year trial data showing that most low-risk cancers can be safely watched rather than treated. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime — yet most will die with it, not from it. Here’s how to think through the decision like a clinician would.
Table of Contents
- What Medicare Covers for Prostate Screening
- The PSA Test: What Your Number Means
- Who Should Be Screened — Current Guidelines
- Newer Tools: MRI and Second-Line Blood Tests
- Active Surveillance: The 15-Year Evidence
- Frequently Asked Questions
What Medicare Covers for Prostate Cancer Screening in 2026
Medicare Part B covers two prostate cancer screening services for men 50 and older (coverage begins the day after your 50th birthday), once every 12 months:
| Screening Service | Frequency | Your Cost (2026) |
|---|---|---|
| PSA blood test | Once every 12 months, age 50+ | $0 — no deductible, no coinsurance |
| Digital rectal exam (DRE) | Once every 12 months, age 50+ | 20% after $283 Part B deductible |
| Follow-up diagnostic tests (MRI, biopsy) if PSA is abnormal | As medically necessary | 20% after deductible (diagnostic, not screening) |
Note the trap many readers hit: the screening PSA is free, but anything that follows an abnormal result — repeat PSA, MRI, urology consult, biopsy — is billed as diagnostic care under regular Part B cost-sharing. A Medigap plan covers that 20%; Medicare Advantage plans set their own copays.
The PSA Test: What Your Number Actually Means
Prostate-specific antigen is a protein made by all prostate tissue — cancerous and benign alike. That’s the test’s fundamental weakness. An enlarged prostate (BPH), prostatitis, a recent urinary infection, ejaculation within 48 hours, even a long bike ride can elevate PSA. Roughly 3 in 4 men with a “positive” PSA between 4 and 10 ng/mL do not have cancer on biopsy.
- Under 1 ng/mL at age 60 — very low lifetime risk of lethal prostate cancer; many specialists would stop or space out screening
- 4–10 ng/mL — the “gray zone”; warrants a repeat test and usually an MRI before any biopsy decision
- PSA velocity matters — a number rising more than ~0.75 ng/mL per year is more concerning than a stable elevated value
- Free-to-total PSA ratio — a low percentage of “free” PSA (under ~10%) points more toward cancer; a high ratio is reassuring
Who Should Be Screened — What the Guidelines Say
The U.S. Preventive Services Task Force recommends that men aged 55–69 make an individual decision after discussing benefits and harms with their doctor, and recommends against routine PSA screening at 70 and older. The American Cancer Society suggests starting the conversation at 50 for average-risk men, at 45 for Black men and men with a father or brother diagnosed before 65, and at 40 with multiple affected relatives.
Why the age-70 cutoff? Because prostate cancer is usually slow-growing, the survival benefit of screening takes roughly a decade to materialize. The honest clinical question isn’t your age — it’s your life expectancy. A vigorous 72-year-old with excellent health and 15+ years ahead may reasonably continue; a 68-year-old with serious heart failure may reasonably stop. This is exactly the conversation to have at your Medicare Annual Wellness Visit.
Newer Tools: MRI Before Biopsy and Second-Line Blood Tests
The biggest change in the screening pathway is multiparametric MRI before biopsy. In the landmark PRECISION trial, MRI-targeted biopsy detected significantly more clinically significant cancers than standard 12-core biopsy while allowing about a quarter of men to skip biopsy entirely when the MRI was clean. Most academic urology centers now consider MRI-first the standard of care for an elevated PSA, and Medicare covers it as a diagnostic test.
Second-line blood and urine tests — the Prostate Health Index (PHI), 4Kscore, and others — refine the odds that an elevated PSA reflects aggressive disease, helping men in the gray zone avoid unnecessary biopsies. Ask your urologist whether one fits your situation before agreeing to a biopsy on PSA alone.
Active Surveillance: What 15 Years of Data Show
If screening does find cancer, a diagnosis is no longer an automatic ticket to surgery. The British ProtecT trial followed men with screen-detected localized prostate cancer for 15 years and found prostate-cancer-specific survival around 97% whether men chose active monitoring, surgery, or radiation. Treatment reduced metastasis rates, but the overall survival difference was negligible — while urinary, sexual, and bowel side effects differed dramatically. For Grade Group 1 (Gleason 6) disease, active surveillance — periodic PSA, MRI, and biopsy — is now the preferred initial approach in major guidelines, sparing most men treatment side effects for years, often forever.
Frequently Asked Questions
Does Medicare pay for a PSA test every year?
Yes. Medicare covers one screening PSA blood test every 12 months for men 50 and older, with no deductible and no coinsurance when the provider accepts assignment. The digital rectal exam is also covered annually but carries 20% cost-sharing.
At what age should a man stop PSA screening?
The USPSTF recommends against routine screening at 70+, but the better measure is life expectancy: if you likely have 10 or more healthy years ahead, continuing can be reasonable. Discuss your overall health, family history, and prior PSA pattern with your doctor.
What is a dangerous PSA level?
There’s no single “dangerous” number. Values above 4 ng/mL traditionally trigger evaluation, but the trend over time, your prostate size, and the free-to-total ratio matter as much as the absolute value. A PSA above 10 ng/mL substantially raises the odds of clinically significant cancer and warrants urology referral.
Can an enlarged prostate cause a high PSA without cancer?
Absolutely — benign prostatic hyperplasia is the most common cause of an elevated PSA in older men. That’s why a single elevated reading should be repeated and usually followed by MRI rather than going straight to biopsy.
Is a prostate biopsy painful or risky?
Modern biopsies are done under local anesthesia and take about 15 minutes. The main risks are infection (lower with the transperineal approach many centers now use), temporary blood in urine or semen, and brief discomfort. MRI-first pathways exist precisely to ensure you only undergo biopsy when it’s truly warranted.
Related Articles You May Find Helpful
- Senior Health Conditions Guide 2026: Complete Resource
- Prostate Health for Senior Men 2026: BPH, PSA & Prevention Guide
- Free Medicare Preventive Screenings 2026: Complete Senior Guide
- Medicare Cancer Treatment Coverage 2026: What Seniors Must Know
- Low Testosterone in Senior Men 2026: 9 Warning Signs & TRT Guide
Sources
- Medicare.gov — Prostate Cancer Screening Coverage
- USPSTF — Prostate Cancer Screening Recommendation
- National Cancer Institute — Prostate Cancer
This article is for educational purposes only and is not a substitute for professional medical advice. Read our medical disclaimer and editorial guidelines.
